ONCT News and Press, Oncternal Therapeutics Inc. From 11/04/20

Rare Pediatric Disease Designation received from FDA for TK216 for treatment of Ewing s arcoma Interim Phase 1 data for TK216 in 15 evaluable patients with relapsed/refractory Ewing s arcoma demonstrated two complete respon...

The FDA grants Rare Pediatric Disease designation to Oncternal Therapeutics' (ONCT) TK216 for the treatment of Ewing sarcoma, an ultra-rare cancerous tumor that grows in the bones or soft tissue around bones.Rare Pediatric Disease designation provides for the issuance of a rare pediatric dise...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for TK216, an investigational p...

Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments Canada NewsWire MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST)...

Oncternal Therapeutics ([[ONCT]] -4.1%) has announced the presentation of interim clinical data from its ongoing Phase 1 trial for TK216, in patients with relapsed or refractory Ewing sarcoma, tumor that forms in bone or soft tissue. Data were presented at European Society for Medic...

- Complete responses reported for two patients with relapsed/refractory Ewing sarcoma treated at the recommended Phase 2 dose of TK216, including a patient who recently improved from a partial to complete response - Enrollment in expansion cohort has accelerated, and data on a...

- H.C. Wainwright 22nd Annual Global Investment Conference - September 14 th - 16 th - Oppenheimer Fall Healthcare Life Sciences & MedTech Summit - September 21 st - 23 rd Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the d...

Gainers:  Just Energy Group (NYSE: JE ) +35% . More news on: Just Energy Group Inc., Nutanix, Inc., FTS International, Inc., Stocks on the move, Read more ...

Due to demand, Oncternal Therapeutics' (NASDAQ: ONCT ) book runner H.C. Wainwright & Co. has agreed to increase the size of its previous offering to purchase ~2.14M shares of common stock (from 1.67M) at $2.10/share, for expected gross proceeds of ~$4.5M. More news on: Oncternal Th...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commi...